Solu-Cortef
To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS
Tel-Aviv Sourasky Medical CenterEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Tel-Aviv Sourasky Medical Center | Early Phase 1 | C |
(+)-VINCRISTINE Tel-Aviv Sourasky Medical Center | Early Phase 1 | C |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →